1. Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma 
Fred Saad 
European Urology Supplements 
Volume 6, Issue 11, Pages (June 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Zoledronic acid consistently reduced all types of skeletal-related events (SREs) at 2 yr in patients with hormone-refractory prostate cancer. HCM: hypercalcemia of malignancy. Adapted from Saad F et al [10,17].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier estimates of time to first skeletal complication for patients treated with 4mg zoledronic acid (ZOL) compared with placebo at 2 yr. SRE: skeletal-related event. Adapted from Saad F et al [10] and with permission from Coleman RE. Oncologist 2004;9(suppl 4):14–27. © AlphaMed Press [18].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Zoledronic acid increases time to first skeletal-related event (SRE) in patients with renal cell carcinoma. NR: not reached. Adapted with permission from Lipton A et al [25].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions